A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer

Saved in:
Bibliographic Details
Published inJournal of Clinical Oncology Vol. 34; p. TPS5608
Main Authors Sharad A. Ghamande, Robert L. Coleman, Susan C. Weil, Kimberly Hoffman, Antonio González-Martín, Ignace Vergote, Luigi Grasso, Hani Gabra, Bradley J. Monk, Keiichi Fujiwara, Deborah K. Armstrong, Jalid Sehouli, Sandro Pignata, Thomas J. Herzog, Charles Schweizer
Format Journal Article
LanguageJapanese
Published American Society of Clinical Oncology (ASCO) 20.05.2016
Online AccessGet full text

Cover

More Information
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2016.34.15_suppl.tps5608